LitAlert ~~ GeneLit.com

    • Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
    • Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Nicholson A, Richards C, Wells-Jordan P, Murphy GJ, Thomas A; MiST1 study group.
    • Lancet Respir Med. 2021 Jan 27:S2213-2600(20)30390-8. doi: 10.1016/S2213-2600(20)30390-8. Epub ahead of print.
    • Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
    • Janysek DC, Kim J, Duijf PHG, Dray E.
    • Transl Oncol. 2021 Jan 27;14(3):101012. doi: 10.1016/j.tranon.2021.101012. Epub ahead of print.